Novartis AG (SWX: NOVN)
Switzerland
· Delayed Price · Currency is CHF
91.06
-0.16 (-0.18%)
Nov 19, 2024, 5:30 PM CET
Novartis AG Revenue
Novartis AG had revenue of $13.17B USD in the quarter ending September 30, 2024, with 8.93% growth. This brings the company's revenue in the last twelve months to $49.94B, up 8.92% year-over-year. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
$49.94B
Revenue Growth
+8.92%
P/S Ratio
4.40
Revenue / Employee
$656.61K
Employees
76,057
Market Cap
182.37B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 60.58B |
Roche Holding AG | 60.58B |
Lonza Group AG | 6.70B |
Galderma Group AG | 3.88B |
Sonova Holding AG | 3.63B |
Straumann Holding AG | 2.54B |
Ypsomed Holding AG | 617.07M |
Galenica AG | 3.80B |
Novartis AG News
- 5 hours ago - Novartis ranks first in 2024 Access to Medicine Index - GlobeNewsWire
- 20 hours ago - Novartis, Ratio to collaborate on SSTR2 radiotherapeutic for cancer - Seeking Alpha
- 1 day ago - Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate - PRNewsWire
- 6 days ago - PPI, Novartis hold media workshop to enhance health literacy in managing cholesterol, promote heart health - BusinessMirror
- 6 days ago - Schrödinger gains on Novartis deal despite Q3 miss - Seeking Alpha
- 7 days ago - Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details - Benzinga
- 7 days ago - Cellares Appoints Ossama Eissa, Former Novartis, Lonza and Legend Biopharma Leader, as Chief Operating Officer - Business Wire
- 7 days ago - Schrödinger’s stock soars 9% as it enters collaboration pact with Novartis for up to about $2.5 billion in payments - MarketWatch